Lengyel Gabriella, Tulassay Zsolt
Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika.
Orv Hetil. 2005 Jun 5;146(23):1245-9.
The primary biliary cirrhosis (PBC) is a chronic, progressive disease of unknown origin with immune pathomechanism. The disease is accompanied with the chronic inflammation of the small and middle intra-hepatic bile ducts. It occurs in 90 per cent of women. The authors summarizes the possibilities ot its therapy after the review of the pathogenesis and clinical findings. They discuss the pathomechanism and the effects on the biochemical and histological findings of ursodeoxycholic acid (UDCA), which is the basis therapy of this disease, The place and indication of immunosuppressive drugs as well as possibilities of immune modulation are also reviewed on the basis of literary data. The therapy in the complication PBC and concomitant diseases are also discussed. The authors mention the opportunities of the therapy which will be applied in the future as a fruitful therapy.
原发性胆汁性肝硬化(PBC)是一种病因不明的慢性进行性疾病,具有免疫发病机制。该疾病伴有肝内中小胆管的慢性炎症。90%的患者为女性。作者在回顾发病机制和临床发现后总结了其治疗的可能性。他们讨论了熊去氧胆酸(UDCA)的发病机制及其对生化和组织学结果的影响,UDCA是该疾病的基础治疗药物。还根据文献资料综述了免疫抑制药物的作用部位和适应证以及免疫调节的可能性。同时也讨论了PBC并发症和伴发疾病的治疗。作者提到了未来可能应用的有效治疗方法。